



ISLE OF WIGHT HEALTH AND WELLBEING BOARD Summary Report

1. Formal details of the paper

1.1. PHARMACEUTICAL NEEDS ASSESSMENT 2018- 2021 (PNA)

1.2. Request to the HWB to delegate authority to the Director of Public Health, in consultation with the Board Chair to make representations to NHS England about pharmacy consolidation applications.

1.2 General publication

1.3 **26 APRIL 2018**

1.4 Frances Tilley frances.tilley@iow.gov.uk

2. Summary

2.1. The PNA is a statement of the needs of the Isle of Wight's population in relation to pharmaceutical services. From 1 April 2013, statutory responsibility for publishing and updating a statement of the need for pharmaceutical services passed to health and wellbeing boards (HWBs). Pharmaceutical Needs Assessments (PNAs) are used when considering applications for new pharmacies in an area and by commissioners to identify local health needs that could be addressed by pharmacy services.

2.2. The Isle Of Wight HWB has a duty to ensure the revised PNA is in place by May 2018 and keep up to date a statement of need for pharmaceutical services. The coordination and production of the Isle of Wight PNA has been delegated to a steering group of partners. This collaborative approach aims to encourage the widest range of stakeholders and those with an interest in the PNA to participate in its development.

2.3. The statutory 60 day public consultation ran from 12th December 2017 to 8th February 2018. The results of the consultation have been included in the PNA.

3. Key Points

3.1. The PNA concludes that the number and distribution of community pharmacies and dispensing doctors on the Isle of Wight is adequate to

provide pharmaceutical services for the local population. There is the potential for maximising service provision of advanced (and enhanced) community pharmacy services which are commissioned by NHS England (Wessex).

- 3.2. The HWB has a statutory duty to make a representation to NHS England on consolidation applications of community pharmacies in its area (i.e. where pharmacy businesses on two or more sites propose to consolidate to a single existing site). This duty is set out in The National Health Service (Pharmaceutical Services, Charges and Prescribing) (Amendment) Regulations 2016.

The following sets out a proposal for the IOW HWB to meet this duty:

- As specified in the regulations, the HWB must provide an opinion to NHS England on whether, if the application were granted, the proposed removal of premises from the pharmaceutical list would or would not create a gap in pharmaceutical services. The decision is informed by the information in the PNA.
- The HWB must respond to NHS England within 45 days of being notified of a pharmacy consolidation application.
- As this period may fall outside the usual schedule of Board meetings it is proposed that in order to meet the statutory deadlines responsibility for decisions regarding pharmacy consolidation are delegated to the Director of Public Health (DPH), in consultation with the HWB Chair.
- The DPH will have delegated authority where, based on information provided in the application and the PNA, the DPH believes that the application does not create a gap in provision.
- Where the DPH, following consultation with the HWB Chair, believes the application will potentially create a gap it is proposed that the DPH will be responsible for consulting within 14 days of notification of the application by electronically circulating the application information, to :
 - a) The Executive Member for Public health
 - b) The Chair of the Health and Wellbeing Board
 - c) Relevant ward members
 - d) Relevant Clinical Commissioning Group lead
 - e) Health Watch
- The DPH, in consultation with the HWB Chair, will be responsible for co-ordinating the response to NHS England
- As part of this process, all those consulted will be required to highlight any potential conflicts of interest which may arise in response to an application.
- NHS England will consider all representations that are received and will arrange an oral hearing to determine the application if a matter is identified on which further evidence is needed.

4. Decisions, recommendations and any options

4.1 The Board is asked to do what:

- Approve the draft PNA for publication by May 2018.
- To delegate authority to the Director of Public Health, in consultation with the HWB Chair, to make representations to NHS England about pharmacy consolidation applications where these are non contentious.

5. References

[Appendix](#) - Pharmaceutical Needs Assessment

Contact Point: Frances Tilley, Senior Public Health Practitioner, ☎ 821000 e-mail frances.tilley@jow.gov.uk

Dr SALLIE BACON
Interim Director of Public Health

CLARE MOSDELL (CLLR)
*Cabinet Member for Adult Social Care
and Public Health*